Literature DB >> 3486953

Tumor size: effect on monoclonal antibody uptake in tumor models.

P L Hagan, S E Halpern, R O Dillman, D L Shawler, D E Johnson, A Chen, L Krishnan, J Frincke, R M Bartholomew, G S David.   

Abstract

Studies were performed to determine the effect of tumor size on the incorporation of radiolabeled monoclonal antitumor antibodies (MoAbs) into human tumors growing in nude mice. The colon tumors ranged in size from 0.03-1.6 g, the melanoma from 0.1 to 6.7 g, and the lymphoma from 0.06 to 10.2 g. Indium-111 was primarily used as the radiolabel, however, both 125I and 111In were used as tracers for the MoAb in one experiment. The per g radiopharmaceutical uptake by tumors was inversely proportional to tumor size when tumor specific MoAb was administered. This finding was independent of the radiolabel and was demonstrable when the mice bore two tumors of differing size. When the MoAb was not specific for the tumor, the data were less well defined and a statistically significant correlation with size did not occur. These data are strong evidence for a decrease in per g uptake of labeled tumor specific antibodies as tumors increase in size.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486953

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  28 in total

1.  Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.

Authors:  Anuradha Soundararajan; Ande Bao; William T Phillips; Linda M McManus; Beth A Goins
Journal:  Cancer Biother Radiopharm       Date:  2011-08-11       Impact factor: 3.099

2.  Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody.

Authors:  Jason L J Dearling; Stephan D Voss; Patricia Dunning; Erin Snay; Frederic Fahey; Suzanne V Smith; James S Huston; Claude F Meares; S Ted Treves; Alan B Packard
Journal:  Nucl Med Biol       Date:  2010-10-27       Impact factor: 2.408

3.  Relationship between tumour size and uptake of radiolabelled anti-CEA in a colon tumour xenograft.

Authors:  R B Pedley; J Boden; P A Keep; P J Harwood; A J Green; G T Rogers
Journal:  Eur J Nucl Med       Date:  1987

Review 4.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

Review 5.  Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption.

Authors:  S E Strand; M Ljungberg; J Tennvall; K Norrgren; M Garkavij
Journal:  Med Biol Eng Comput       Date:  1994-09       Impact factor: 2.602

6.  Effects of tumour mass and circulating antigen on the biodistribution of 111In-labelled F(ab')2 fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts.

Authors:  M Perälä-Heape; P Vihko; A Laine; J Heikkilä; R Vihko
Journal:  Eur J Nucl Med       Date:  1991

7.  Human breast tumor imaging using 111In labeled monoclonal antibody: athymic mouse model.

Authors:  B A Khaw; J S Bailes; S L Schneider; J Lancaster; J Powers; H W Strauss; J C Lasher; W L McGuire
Journal:  Eur J Nucl Med       Date:  1988

8.  Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.

Authors:  Sarah M Cheal; Hong Xu; Hong-Fen Guo; Sang-Gyu Lee; Blesida Punzalan; Sandhya Chalasani; Edward K Fung; Achim Jungbluth; Pat B Zanzonico; Jorge A Carrasquillo; Joseph O'Donoghue; Peter M Smith-Jones; K Dane Wittrup; Nai-Kong V Cheung; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-24       Impact factor: 9.236

9.  Radioimmuno-guided endoscopy (RIGE) in the detection of primary and recurrent rectal tumor.

Authors:  U Prati; L Roveda; R Butera; S Nazari; E Trespi; C Aprile; A Zonta
Journal:  Int J Colorectal Dis       Date:  1992-09       Impact factor: 2.571

10.  Optimum combination of targeted 131I therapy and total-body irradiation for treatment of disseminated tumors of differing radiosensitivity.

Authors:  A E Amin; T E Wheldon; J A O'Donoghue; A Barrett
Journal:  Cell Biophys       Date:  1992 Aug-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.